| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/14/2001 | WO2001042234A1 3-methyl-chroman and -thiochroman derivatives |
| 06/14/2001 | WO2001042233A1 Optically active chroman and thiochroman derivatives |
| 06/14/2001 | WO2001042231A2 Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042216A2 Caspase inhibitors and uses thereof |
| 06/14/2001 | WO2001042179A1 Compounds which mimic the chemical and biological properties of discodermolide |
| 06/14/2001 | WO2001041823A2 Radioactive compositions and methods of use thereof |
| 06/14/2001 | WO2001041810A2 Nucleic acid delivery system |
| 06/14/2001 | WO2001041809A1 Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus |
| 06/14/2001 | WO2001041804A1 Modulation and assay of fx activity in cells in cancer, inflammatory responses and diseases and in autoimmunity |
| 06/14/2001 | WO2001041801A2 Mutant simplex virus for treating unwanted hyperproliferative cell growth |
| 06/14/2001 | WO2001041799A1 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041791A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 06/14/2001 | WO2001041790A1 Botulinum toxin for reducing catecholamine secretion |
| 06/14/2001 | WO2001041788A1 INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| 06/14/2001 | WO2001041787A1 INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| 06/14/2001 | WO2001041782A2 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 06/14/2001 | WO2001041768A2 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041747A2 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer |
| 06/14/2001 | WO2001041741A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001027101A3 Anhydrous salt |
| 06/14/2001 | WO2001018040A3 Use of leptin in inhibition of endothelial cell proliferation |
| 06/14/2001 | WO2001016133A3 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/14/2001 | WO2001009189A3 Compositions and methods for the treatment of tumors |
| 06/14/2001 | WO2001009113A3 Heterocyclic compounds inhibiting angiogenesis |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | WO2001000829A8 Human endogenous retrovirus in breast cancer |
| 06/14/2001 | WO2001000812A3 22012, a novel human carboxypeptidase |
| 06/14/2001 | WO2000035950A9 Reagents and methods useful for detecting diseases of the breast |
| 06/14/2001 | WO2000032631A3 Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof |
| 06/14/2001 | WO1999067250A8 Syntheses of a variety of lamellarin compounds and analogues |
| 06/14/2001 | WO1998037194A9 Ell2, a member of an ell family of rna polymerase ii elongation factors |
| 06/14/2001 | US20010003779 Camptothecin analogs and methods of preparation thereof |
| 06/14/2001 | US20010003742 Antilipemic formulation |
| 06/14/2001 | US20010003585 Introducing a viral expression vector having a tumoricidal or susceptibility gene into a mammalian cell and attaching the cell to a support matrix in vitro; transferring the supported cells to mammalian tumor cells; durability; brains |
| 06/14/2001 | CA2733434A1 Caspase inhibitors and uses thereof |
| 06/14/2001 | CA2395039A1 Method for identifying inhibitors of cytokinesis |
| 06/14/2001 | CA2394917A1 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | CA2394891A1 Substituted phthalocyanines and their precursors |
| 06/14/2001 | CA2394303A1 Interferon-alpha induced gene |
| 06/14/2001 | CA2393968A1 Compounds which mimic the chemical and biological properties of discodermolide |
| 06/14/2001 | CA2393960A1 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393859A1 Apoptin-associating protein |
| 06/14/2001 | CA2393738A1 Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393730A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | CA2393688A1 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 06/14/2001 | CA2393662A1 Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393539A1 Radioactive compositions and methods of use thereof |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393526A1 Nucleic acid delivery system |
| 06/14/2001 | CA2393463A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 06/14/2001 | CA2393339A1 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392764A1 Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
| 06/14/2001 | CA2392740A1 Il-6 like polynucleotides, polypeptides, and antibodies |
| 06/14/2001 | CA2392584A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | CA2390093A1 Extracellular matrix and cell adhesion molecules |
| 06/14/2001 | CA2384982A1 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | CA2362649A1 Antibodies binding to human trypsin-like protease and methods for utilizing the same |
| 06/14/2001 | CA2361563A1 Use of polyacrylamide gel for forming a connective-tissue capsule in a mammal for cultivating allogenic or xenogenic cells |
| 06/13/2001 | EP1107005A1 Method for identifying inhibitors of cytokinesis |
| 06/13/2001 | EP1106615A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106614A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106612A1 Quinoline derivatives useful for inhibiting farnesyl protein transferase |
| 06/13/2001 | EP1106610A1 Farnesyl transferase inhibiting 2-quinolone derivatives |
| 06/13/2001 | EP1106183A2 Antibodies to erbB2 and their therapeutic uses |
| 06/13/2001 | EP1106180A1 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/13/2001 | EP1106179A2 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 06/13/2001 | EP1106177A1 Tumor tissue accumulation enhancers for drugs |
| 06/13/2001 | EP1105738A1 Assays, methods and means for modulating nuclear localisation |
| 06/13/2001 | EP1105538A2 HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS |
| 06/13/2001 | EP1105528A1 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 06/13/2001 | EP1105518A1 USE OF mCRP FOR DELIVERY OF MATERIALS INTO CELLS |
| 06/13/2001 | EP1105513A2 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 06/13/2001 | EP1105512A1 Intracellular delivery vehicles |
| 06/13/2001 | EP1105504A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 06/13/2001 | EP1105483A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 06/13/2001 | EP1105481A2 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use |
| 06/13/2001 | EP1105480A1 14274 receptor, a g-protein coupled receptor related to the edg receptor family |
| 06/13/2001 | EP1105478A1 Extracellular adhesive proteins, exadh1 and exadh2 |
| 06/13/2001 | EP1105466A1 Process for purifying human papillomavirus virus-like particles |
| 06/13/2001 | EP1105412A1 Serine protease inhibitors comprising alpha-keto heterocycles |
| 06/13/2001 | EP1105395A1 Photocyclized rapamycins |
| 06/13/2001 | EP1105389A1 Integrin receptor antagonists |
| 06/13/2001 | EP1105384A1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors |
| 06/13/2001 | EP1105383A2 Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| 06/13/2001 | EP1105379A1 Water soluble analogs and prodrugs of paclitaxel |
| 06/13/2001 | EP1105378A1 Quinazoline derivatives |
| 06/13/2001 | EP1105160A1 Lats knock-out animal models and their uses |
| 06/13/2001 | EP1105157A1 Protein delivery system using human papillomavirus virus-like particles |
| 06/13/2001 | EP1105155A1 Vaccine comprising cytokine-induced heat shock proteins (hsp) |
| 06/13/2001 | EP1105154A1 Bacterial superantigen vaccines |
| 06/13/2001 | EP1105150A1 Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor |